|
Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.
|
| | | Contact Information | |
Address: |
200 Connell Dr.
Berkeley Heights, NJ 07922
| | Phone: | 908-286-9800 | | Fax: | 908-464-1701 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.40 M | | Revenue Growth (1 yr): | (-37.40%) | | Employees (2008): | 25 | | Employee Growth (1 yr): | (-46.80%) |
|
|
Key People
| | • |
Chairman and CEO:
Raymond P. Warrell Jr.
| | • |
SVP and COO:
W. Lloyd Sanders
| | • |
VP Finance:
Gary Siegel
|
|
|
